VERTEX PHARMACEUTICALS INC
NASDAQ: VRTX (Vertex Pharmaceuticals Incorpor)
最近更新时间: 5小时之前535.17
10.65 (2.03%)
| 前收盘价格 | 524.52 |
| 收盘价格 | 525.62 |
| 成交量 | 1,641,340 |
| 平均成交量 (3个月) | 1,180,817 |
| 市值 | 135,644,684,288 |
| 市盈率 (P/E TTM) | 30.99 |
| 预期市盈率 (P/E Forward) | 24.10 |
| 价格/销量 (P/S) | 10.51 |
| 股市价格/股市净资产 (P/B) | 6.46 |
| 52周波幅 | |
| 利润日期 | 2 Nov 2026 |
| 营业毛利率 | -8.91% |
| 营业利益率 (TTM) | 37.22% |
| 稀释每股收益 (EPS TTM) | -3.80 |
| 季度收入增长率 (YOY) | 3.00% |
| 季度盈利增长率 (YOY) | -41.20% |
| 总债务/股东权益 (D/E MRQ) | 10.00% |
| 流动比率 (MRQ) | 2.65 |
| 营业现金流 (OCF TTM) | -980.30 M |
| 杠杆自由现金流 (LFCF TTM) | 2.63 B |
| 资产报酬率 (ROA TTM) | 11.77% |
| 股东权益报酬率 (ROE TTM) | -5.64% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Vertex Pharmaceuticals Incorpor | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 相对估值 | -5.0 |
| 财务健康 | 5.0 |
| AI Insight | NA |
| 平均 | 1.00 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Value |
| 内部持股比例 | 0.15% |
| 机构持股比例 | 97.64% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Loomis Sayles & Co L P | 30 Jun 2026 | 3,920,953 |
该时间范围内无数据。
AI 技术分析
打开“技术”标签以生成最新分析。
投资组合